Shares of QYUNS-B (ASX: 02509) jumped more than 8% following an announcement regarding a planned acquisition. At the time of writing, the stock was up 8.18% to HK$14.81, with a turnover of HK$2.98 million.

The company disclosed that on June 26, 2026, its wholly-owned subsidiary, Saifu JV, entered into a share transfer agreement with Taizhou Huacheng. Under the agreement, Saifu JV conditionally agreed to acquire, and Taizhou Huacheng conditionally agreed to sell, the target equity representing approximately 34.0001% of the shares in Saifus. The total consideration for the transaction is RMB 86.02 million.

Prior to this announcement, the company indirectly held approximately 65.9999% of Saifus through Saifu JV. Upon completion of the acquisition, the company will indirectly own 100% of Saifus through its subsidiary.

Saifus is described as the company's subsidiary focused on Chemistry, Manufacturing, and Controls (CMC). Its responsibilities encompass the group's cell line development, process development, formulation development, analytical method development, quality control, quality assurance, pilot-scale production, and commercial manufacturing.

Strategic Rationale for the Transaction

The primary objective of the acquisition is to facilitate the smooth submission and regulatory approval of New Drug Applications (NDAs) for two of the group's core pipeline products. These are Lusekitamab (QX002N, an anti-IL-17A monoclonal antibody) and Autokibimab (QX005N, an anti-IL-4Rα monoclonal antibody).

Additional Expected Benefits

Concurrently, the move aims to consolidate the group's resources, strengthen internal synergies, optimize the management structure, and further enhance the governance effectiveness and operational efficiency of Saifus.